CLINUVEL PHARMACEUTICALS

We are a global biopharmaceutical company committed to developing drugs for the treatment of a range of severe skin disorders.

CLINUVEL’s lead product, SCENESSE® (afamelanotide 16mg), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe. In December 2014 the European Commission granted SCENESSE® marketing authorisation under exceptional circumstances for the prevention of phototoxicity in adult patients with EPP. Further trials of SCENESSE® are underway in the pigmentary disorder vitiligo.

Our website has been developed to help share our expertise on the interaction of light and human skin as well as provide a thorough overview of our global drug development programs.

Latest Company Announcements

16 October 2017

CLINUVEL Newsletter - October 2017

I am addressing you during quite a turbulent period, when our teams are preparing various dossiers to meet regulatory obligations in Europe and the US

Read More
10 October 2017

CLINUVEL CONFIRMS AGM DATE

CLINUVEL PHARMACEUTICALS LTD today announced it will hold its 2017 Annual General Meeting of shareholders on Tuesday 28 November 2017

Read More
04 October 2017

ELIE ISHAG TO RETIRE FROM CLINUVEL BOARD

CLINUVEL today announced that Mr Elie Ishag has advised that he will not stand for re-election as Non-Executive Director of CLINUVEL at the Company’s 2017 Annual General Meeting

Read More
19 September 2017

CLINUVEL PROVIDES UPDATE ON SCENESSE® FDA FILING

CLINUVEL PHARMACEUTICALS LTD today announced an update on its submission of the New Drug Application (NDA) for CLINUVEL’s drug SCENESSE® (afamelanotide 16 mg) to the US Food and Drug Administration (FDA).

Read More
06 September 2017

Appendix 3B

Appendix 3B - New issue announcement

Read More
30 August 2017

Appendix 4E - Preliminary Final Report 2016/17

Appendix 4E - Preliminary Final Report 2016/17

Read More

Quick Links